Development of a novel drug candidate with a first-in-class mechanism for smoking cessation, relapse and abstinence
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01DA047791
- Recipient
-
Astraea Therapeutics LLC UEI ZNNQAFC5FXH3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,946,553
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Mountain View, CA 94043, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $646,565 | |
| Amendment | $0 | |
| Amendment | $2,158,836 | |
| Amendment | $0 | |
| Original award | $1,141,152 |
Quick answers
Who received award U01DA047791?
U01DA047791 was awarded to Astraea Therapeutics LLC by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2018.
How much is award U01DA047791 worth?
$3,946,553 has been obligated on U01DA047791.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award